Device Trial Radar · NCT04775537
OssiMend BA in Posterolateral Instrumented Lumbar Fusion
Last checked: Nov 20, 2026Latest source record: Oct 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Jan 21, 2021
Primary completion
Dec 30, 2026
Study completion Jan 30, 2027
Sponsor
- Lead sponsor
- Collagen MatrixNot on our public-company list
- Sponsor type
- Industry
- First posted
- Mar 1, 2021
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to measure the success rate of lumbar fusion in subjects at 12 months when instrumented lumbar arthrodesis is performed using OssiMend Bioactive Moldable as the bone grafting material
Conditions
- Spinal Disease
- Degenerative Disc Disease
Interventions
OssiMend™ Bioactive MoldableDevice
Lumbar Spine fusion with OssiMend™ Bioactive Moldable
Primary outcomes
What the sponsor says the trial is designed to measure.
- Fusion SuccessTime frame: 12 months
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
San Diego Neurosurgery
Encinitas, California · Not yet recruiting
Hartford Hospital
Hartford, Connecticut · Recruiting
University Orthopaedic Associates, Division of OrthoNJ
Somerset, New Jersey · Not yet recruiting
1 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.